首页> 外文期刊>Clinical oncology >Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.
【24h】

Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.

机译:胃癌术后放化疗:采用和适应。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: Intergroup study 0116 (INT-0116) showed an 11% absolute improvement in 3-year survival with post-operative radiochemotherapy for gastric cancer, but reported 33% severe acute GI toxicity using conventional simulation with large fields. We adapted the treatment using conformal radiotherapy techniques and assessed toxicity and outcome in 20 consecutive patients. METHODS: A conformal radiotherapy technique previously developed for gastric lymphoma was adapted to treat the target volume defined in INT-0116. The five-field plan used a large anterior field, plus asymmetrically matched upper AP:PA fields and lower lateral fields. Consecutive patients with ECOG PS 0-2 and stage IB-IV non-metastatic gastric cancer were treated with 5-FU (425 mg/m2 daily x 5 days) and leucovorin (20 mg/m2 daily x 5 days) for one cycle prior to and two cycles following concurrent radiation (45 Gy/25 fractions) with identical drug dosages on the first 4 and last 3 days of radiation. Acute toxicity was prospectively recorded weekly using RTOG and NCI common toxicity criteria. Patient charts were reviewed in November 2003 and late toxicity and outcome were recorded. RESULTS: Nineteen of 20 patients completed radiotherapy and 14 completed all chemotherapy cycles. One patient died of neutropenic sepsis. Maximum acute toxicity [grade (number)] was: 5(1), 4(0), 3(4), 2(10), 1(4), 0(1). There were two grade 1 late toxicities. Two-year overall survival is 70% (95% confidence interval: 50-90). CONCLUSIONS: Conformal radiotherapy may improve acute toxicity (25% grade 3 or greater toxicity as compared with 41% reported in INT-0116). Survival is comparable to that achieved in the INT-0116 treatment arm (approximately 60% at 2 years). INT-0116 results can be achieved outside a study setting; however, further efforts to improve treatment efficacy and minimize toxicity are warranted.
机译:目的:小组间研究0116(INT-0116)显示,胃癌术后放射化学疗法的3年生存率绝对改善11%,但使用大范围的常规模拟方法报告了33%的严重急性胃肠道毒性。我们采用保形放疗技术调整了治疗方法,并评估了连续20例患者的毒性和预后。方法:先前针对胃淋巴瘤开发的适形放疗技术适用于治疗INT-0116中定义的目标体积。五场计划使用较大的前场,以及不对称匹配的上部AP:PA场和下部横向场。患有ECOG PS 0-2和IB-IV期非转移性胃癌的连续患者接受5-FU(每天425 mg / m2 x 5天)和亚叶酸(每天20 mg / m2 x 5天)治疗一个周期在同时进行的辐射(45 Gy / 25馏分)照射后的第一个和第二个周期中,在辐射的前4天和后3天使用相同的药物剂量。每周使用RTOG和NCI常见毒性标准预先记录急性毒性。于2003年11月对患者图表进行了回顾,并记录了后期毒性和预后。结果:20例患者中有19例完成了放疗,14例完成了所有化疗周期。 1例患者死于中性粒细胞减少性败血症。最大急性毒性[等级(数)]为:5(1),4(0),3(4),2(10),1(4),0(1)。有两种1级晚期毒性。两年总生存率为70%(95%置信区间:50-90)。结论:适形放疗可改善急性毒性(25%3级或更高毒性,而INT-0116中报道为41%)。存活率与INT-0116治疗组的存活率相当(2年时约60%)。 INT-0116的结果可以在学习环境之外获得;然而,需要进一步努力以提高治疗效果并使毒性最小化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号